검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration)) Daiichi Sankyo·Non-Small Cell Lung Cancer Metasta… ORR 64% |
|---|---|
Overview Program | Patritumab Deruxtecan (Up-Titration) |
Overview Company | Daiichi Sankyo |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer |
MoA Biomarker | biomarkers will give new insights on individual MTX metabolism and drug adherence |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumour growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.. Most mechanically ventilated intensive care unit patients require sedation and analgesia for comfort. Current usual care is propofol-based sedation plus an opioid analgesic. The alpha2 agonists dexmedetomidine and clonidine are potenti… |
Clinical Primary efficacy | ORR 64% |
Clinical ORR | 56% |
Clinical PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT04619004 |
Clinical Data Tier / Score | A · 61 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration)) Daiichi Sankyo·Non-Small Cell Lung Cancer Metasta… ORR 64% |
|---|---|
Overview Program | Patritumab Deruxtecan (Up-Titration) |
Overview Company | Daiichi Sankyo |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer |
MoA Biomarker | biomarkers will give new insights on individual MTX metabolism and drug adherence |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | tumour growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.. Most mechanically ventilated intensive care unit patients require sedation and analgesia for comfort. Current usual care is propofol-based sedation plus an opioid analgesic. The alpha2 agonists dexmedetomidine and clonidine are potenti… |
Clinical Primary efficacy | ORR 64% |
Clinical ORR | 56% |
Clinical PFS | 5.5 |
Clinical Result source | ClinicalTrials.gov NCT04619004 |
Clinical Data Tier / Score | A · 61 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교